THOMAS W BURKE to Paclitaxel
This is a "connection" page, showing publications THOMAS W BURKE has written about Paclitaxel.
Connection Strength
0.442
-
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
Score: 0.270
-
Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006 Oct; 103(1):155-9.
Score: 0.042
-
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005 May; 97(2):489-96.
Score: 0.039
-
Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul; 82(1):156-61.
Score: 0.030
-
Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995 Jul 01; 76(1):116-20.
Score: 0.020
-
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
Score: 0.015
-
The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004 Sep 01; 22(17):3517-23.
Score: 0.009
-
Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):168-73.
Score: 0.009
-
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300.
Score: 0.007